Company / Depreciation & Amortization
BeOne Medicines Ltd. Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$141.7M
FY2025
5-year range
$46.5M / $171.8M
FY2021-FY2025
Trend
-17.5%
vs FY2024
Sector context
#16 of 163
Health Care
What the data says
Among 163 Health Care companies, BeOne Medicines Ltd. is in the bottom 10% for depreciation & amortization. Increased from $88M to $142M over the past 2 years.
Based on SEC 10-K filings.
$142M in FY2025 with a 5-year CAGR of +34.8%. Top quartile in the Health Care sector.
Increased from $88M to $142M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +28.8%
- 5-Year CAGR
- +34.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 163This company $141.7M Sector average $219.4M
▼
-35.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +34.8%, indicating consistent growth.
- In FY2025, depreciation & amortization decreased 17.5% year-over-year.
- Ranks #16 out of 163 companies in the Health Care sector.
- Peak depreciation & amortization was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.82 (distress zone, below 1.8 threshold)
- Negative profit margin: -16.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $141.7M | -17.5% |
| FY2024 | $171.8M | +95.9% |
| FY2023 | $87.7M | +32.3% |
| FY2022 | $66.3M | +42.7% |
| FY2021 | $46.5M | +46.1% |
| FY2020 | $31.8M | +70.8% |
| FY2019 | $18.6M | +79.2% |
| FY2018 | $10.4M | +118.3% |
| FY2017 | $4.8M | +149.2% |
| FY2016 | $1.9M | +23.6% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026